EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
The new agreement builds on previous collaborations between Just – Evotec Biologics and ABL to design highly efficient manufacturing processes for broadly neutralising antibodies (“bNAbs”) against HIV.
- The new agreement builds on previous collaborations between Just – Evotec Biologics and ABL to design highly efficient manufacturing processes for broadly neutralising antibodies (“bNAbs”) against HIV.
- Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited to expand our long-standing partnership with ABL to include the development of a third bNAb.
- The development of safe and efficacious HIV-1 treatments and prevention strategies remains one of the highest priorities of the NIAID.
- No financial details of the agreement between Just – Evotec Biologics and ABL were disclosed.